Consensus Telix Pharmaceuticals Limited Nasdaq

Stocks

TLX

US87961M1053

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-02 EDT			5-day change	1st Jan Change
10.55 ^USD	-1.59%		-7.86%	+40.85%

09-10	ASX Biggest Losers	MT
09-02	ASX Biggest Gainers	MT

2dc89ba93cc8b2d38c6bbc.ldHpXmX63k7dghxBAHoRDR_B3DYAR1izXnlrbdfkbaw.1qOICB2vpwPkwGkHayVyRVGNi3dqFx-LNAwgD4GUAZvX5rYsVJKHPbrMaw~151dedeba14ba6b43c348ea1d5170750

Analysts' recommendations: Telix Pharmaceuticals Limited

09-15	Jarden Adjusts Telix Pharmaceuticals' Price Target to AU$21 from AU$20.70, Keeps at Buy	MT
09-15	Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says	MT
07-21	Telix Pharmaceuticals Carries Meaningful Upside on Potential Product Approvals, Jefferies Says	MT
07-17	RBC Downgrades Telix Pharmaceuticals to Sector Perform From Outperform, Keeps AU$18 Price Target	MT
07-03	Telix Pharmaceuticals Securing FDA Nod in Line With Expectations, Says Jefferies, Shares Down 3%	MT
04-15	Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says	MT
04-12	Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says	MT
04-08	Jarden Adjusts Telix Pharmaceuticals's Price Target to AU$21.80 from AU$21, Keeps at Buy	MT
04-07	Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies	MT
03-01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
01-21	Telix Pharmaceuticals Poised for Growth With Strong Illuccix Sales, Gozellix Launch, Jefferies Says	MT
01-13	Telix Pharmaceuticals Reaffirms Guidance Amid Imminent Drug Launches in US, Says Jefferies	MT
12-11	Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says	MT
11-12	Alerts from law firm on Telix pharmaceuticals withdrawn	RE
11-11	Telix Reports Positive Results from TLX250-CDx Imaging Trial in Triple Negative Breast Cancer Patients, Shares Fall 3%	MT
25-10-07	Barrenjoey Markets Starts Telix Pharmaceuticals at Overweight with AU$22 Price Target	MT
25-09-24	Telix Pharmaceuticals' Gozellix Expected to See Strong Sales Growth After TPT Status Grant, Jarden Research Says	MT
25-09-23	UBS Adjusts Price Target on Telix Pharmaceuticals to $20 From $23, Maintains Buy Rating	MT
25-09-19	Telix Pharmaceuticals Shows Strong Growth Potential With Blockbuster Drug Prospect, Citi Says	MT
25-09-18	Citigroup Initiates Telix Pharmaceuticals at Buy With $22 Price Target	MT
25-08-21	Telix Pharmaceuticals' Profitability Expected to Rebound, Wedbush Says	MT
25-08-06	Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$27.61 from AU$29.14; Keeps at Buy	MT
25-07-03	HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	MT
25-06-05	Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	MT
25-01-27	UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+27.75%
	LONZA GROUP AG					+21.67%
	REVOLUTION MEDICINES, INC.					+24.6%
	IQVIA HOLDINGS INC.					+11.82%
	BEONE MEDICINES AG					+21.07%
	CELLTRION, INC.					+46.63%
	WUXI BIOLOGICS (CAYMAN) INC.					+6.77%
	BIONTECH SE					+20.91%
	Average					+21.44%
	Weighted average by Cap.					+20.73%